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Executive Summary 
 
The biofilms produced and maintained by Pseudomonas aeruginosa in the lungs of cystic 
fibrosis patients are difficult to treat and can have fatal effects. Antibiotics are necessary to 
control and eliminate these bacterial biofilms, but in vivo administration may not be the most 
effective means. Tobramycin, a commonly used antibiotic for treating cystic fibrosis patients, 
has been commercially developed into a solution that is inhalable via nebulizer. Inhaling this 
mist form of the antibiotic will allow administration of higher concentrations at the site of 
infection. The goal of this study was to develop a model using COMSOL Multiphysics to better 
understand the distribution of tobramycin to bacterial biofilms in the lungs. Like nearly all 
medications, tobramycin can become toxic at high concentrations. Since filtration from the blood 
stream is the only significant mechanism of tobramycin elimination, the kidneys are at the 
greatest risk for toxicity. Therefore the study focused on the possibility of maintaining safe blood 
serum concentrations while providing sufficient doses to inhibit the bacteria occupying the lungs. 
The model showed that the bacteria’s minimum inhibitory concentration was easily achievable 
throughout the biofilm while keeping the blood serum concentrations at a safe level. 
Introduction  
 
Background   
Cystic fibrosis (CF) is a genetically inherited disease that affects one out of 3,500 births 
in Europe and North America (1). There is no cure for CF and all patients eventually develop 
chronic obstructive lung disease, which has a 90% mortality rate among CF patients (2).  Patients 
with CF have malfunctioning glands that cause them to have thick and dry mucus, which 
obstruct biological passageways like the lungs.  Normally, the mucus lies on top of a surface-
liquid that acts as a lubricant and entrapped particles are removed along with the mucus by 
beating of the cilia or coughs. The lubrication is partially controlled by chlorine channels, but for 
CF patients these channels do not function properly and this leads to a lack of lubrication. As a 
result, stagnant mucus accumulates and bacteria trapped in the mucus proliferate, which can 
cause serious complications that could lead to death. In fact, life expectancy of people with CF is 
about 45 years. (3)  
Bacteria growing in the mucus are very hard to eliminate without antibiotics because they 
are immune from the host's defenses in contrast to their free-floating counterpart (4). The most 
common and lethal bacterial infection in patients with CF is caused by the bacteria Pseudomonas 
aeruginosa. Tobramycin is an antibiotic often administered to treat CF patients with a P. 
aeruginosa infection (5). It is delivered intravenously, but this requires high dosages because 
intravenous drugs are spread throughout the body and only a small portion of the dose reaches 
the deep lung.  In addition, the dose of tobramycin that can be administered is limited because it 
is toxic to the kidney.  An alternate delivery method is through inhalation of tobramycin particles 
delivered via nebulizers, which provide mist forms of the drug. Tobramycin Inhalation Solution 
(TOBI) is one such device already in use. TOBI delivers the drug directly to the lungs so it 
requires less of the drug than intravenous delivery.  
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Design Objectives  
Our first objective in creating this simulation is to accurately model tobramycin’s 
diffusion through the biofilm and alveolar tissue, which can be done using COMSOL 
Multiphysics software.  By using this model to further evaluate the effects of tobramycin in a 
biofilm of a cystic fibrosis patient, we will then seek to optimize the dosing of tobramycin. 
Specifically, we will determine the ideal dosing time and concentration that (a) achieves 95% 
inhibition of the bacteria with the tobramycin concentration reaching 4 μg/mL in the biofilm (6), 
(b) does not exceed the toxic trough concentration (the concentration immediately before taking 
a second dose) of 2 μg/mL in the blood, and (c) does not exceed the toxic peak concentration of 
12 μg/mL in the blood (7,8). Meeting these requirements will allow for effective treatment while 
avoiding kidney damage, keeping in mind that some parameters may vary due to the fact that 
patients range from infants to elderly adults.  Having not only the dose but the proper 
administration time frame will define the treatment regimen  that best alleviates mucus buildup 
due to biofilm formation in the lungs. 
Problem Schematic  
To implement this model in COMSOL, an effectively one-dimensional geometry was 
chosen to represent a thin slice of a high generation alveolus (Figure 1). This model assumes the 
alveolus is perfectly spherical and fully surrounded by capillary beds. Also, the air and biofilm 
within each alveolus is homogenous and evenly distributed. Since a high generation alveolus is 
modeled, the air layer near the biofilm is approximated as stagnant. The thickness of the air layer 
was chosen by taking half the difference between the alveolar radius and the biofilm thickness. 
Average biofilm and alveolar wall thicknesses are 33 μm and 4 μm, respectively (9, 10). The 
height of the blood layer is the radius of an average capillary. This allows the bottom boundary 
condition to be set as the average blood concentration. (Governing equations, boundary 
conditions and initial conditions can be found in Appendix A while the finalized mesh and mesh 
convergence are located in Appendix B.) 
   
 
Figure 1. Two dimensional geometry used in COMSOL model to represent one-dimensional 
transport of antibiotic from air to biofilm to the bloodstream. 5 
 
 
Results and Discussion  
 
Diffusion of aerosolized tobramycin was modeled in COMSOL using the schematic 
outlined above as well as mass transport and balance equations and input parameters described in 
Appendix A . To perform the finite element analysis in COMSOL, an accurate structured mesh 
was determined through mesh convergence analysis (Appendix B) for the geometry in Figure 1. 
The blood and biofilm concentrations were of particular concern in our analysis, since a 
minimum inhibitory concentration (MIC) of 4 μg/mL must be obtained in the biofilm while 
keeping the blood serum concentration below the toxic limits. For tobramycin, peak and trough 
toxic concentrations in the blood are listed in the literature as 12 μg/mL and 2 μg/mL, 
respectively (8).  
To determine initial dosing regimens, the prescription information for a commercialized 
form of this drug (TOBI) was used. It recommended taking the antibiotic via nebulizer every 8 – 
12 hours; and each administration should last approximately 15 minutes. The 60 mg/mL vial of 
tobramycin solution is converted to approximately 2.25 μg/mL when nebulized, based on a linear 
approximation from values given in Weber et al. 1993 (5). We assumed that each breath during 
the administration would bring the nebulized concentration of tobramycin into the model 
alveolus. While using the nebulizer, the boundary condition of the stagnant airspace in the 
alveolus is assumed to be held at this constant concentration. Once the dosing is complete, the 
boundary will become insulated due to the effectively stagnant air in high generation alveoli.  
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The air and biofilm concentrations equilibrate to the approximate dosage concentration 
within the 15 minute administration (Figure 2). The lower diffusivity through the alveolar wall 
creates a concentration gradient, allowing the blood concentration to remain slightly lower.  The 
diffusivity through the biofilm is two orders of magnitude larger than that of the tissue, allowing 
the drug to move through the biofilm more quickly. This model can only account for simple 
diffusion without the effects of binding or cellular uptake due to the very limited literature on 
biofilm transport. Since the model is based on simple diffusion, the biofilm concentration cannot 
reach 4 μg/mL if the boundary condition is only 2.25 μg/mL. Therefore, a concentration greater 
than that calculated from the TOBI prescription information must be used for effective treatment 
in this model.  
After the 15 minute dose, the top boundary condition was adjusted as described 
previously and the model was allowed to run for an additional 7 hours and 45 minutes to 
determine effects of renal elimination from the bloodstream (Figure 3). After this “off” period, 
the concentration of drug in the biofilm (measured at the center) decreased significantly by 
75.1%.  Within the alveolar wall and blood subdomains, similar results were acquired with a 
74.7% decrease in the tissue and a 74.4% decrease in the blood.  
The combined 8-hour dose and off period were then run repeatedly to determine the 
dynamics of tobramycin concentration in the biofilm and blood. Simulation of repeated dosing 
showed that only two doses are required to reach equilibrium peak and trough concentrations for 
both the center biofilm concentration and the blood concentration (Figure 4 b,c). The 
concentration of tobramycin in air and biofilm throughout administration of the drug (the first 15 7 
 
minutes) appears to be constant as a consequence of the constant concentration boundary 
condition (cT,0 = 2.25 µg/mL) and the high diffusivity of the drug through the air and biofilm 
(Figure 4a). The time it takes for the biofilm concentration to equilibrate with the approximate 
dosage concentration is less than 30 seconds. Based on our mathematical model, there cannot be 
any accumulation above the dosage concentration. This means the dosage concentration must be 
increased in order to achieve the minimal inhibitory concentration for the bacteria.  
 
 
 
 
Figure 4. (a) Biofilm concentration (at center of biofilm) following one 15-minute dose. (b) Biofilm 
concentration over 3 administrations. (c) Blood concentration over 3 administrations. 8 
 
Accuracy Check  
The toxicity of tobramycin is not well defined in the literature. There are references that 
indicate the potential toxic concentration of tobramycin is 2.0 µg/mL (7), but no time span is 
indicated. Clearly there must be some time and concentration combination that will produce 
toxic effects. There have been various studies that have used serum concentrations greater than 
2.0 µg/mL for 4 hours or more without noticeable side effects (11,12). Another publication states 
that toxic peak and trough concentrations of tobramycin are 12 µg/mL and 2.0 µg/mL, 
respectively (8). These values agree with the literature (11,12) that use higher concentrations 
without any signs of toxicity, so we will base our analysis and design constraints on this 
information (Figure 5).  
 
Figure 5. Removal of tobramycin from bloodstream by kidneys over 8 hour period between 
doses. Dosage concentration used in model was 7.5 µg/mL to match initial concentration in 
literature (9). Tobramycin was administered intravenously in the study, so there is no drug flux 
into the bloodstream over time as there is in the model. Therefore, the effective removal rate in 
the model is lower. Data from literature represents average serum concentration for patients with 
standard deviation bars.  
 
Sensitivity Analysis  
We completed a sensitivity analysis for six parameters in our model including dosage of 
tobramycin, time of inhalation, number of doses, half-life of tobramycin and diffusivity of 
tobramycin through biofilm and tissue. Parameters were varied one at a time to determine the 
relative effect each has on the solution.  
The dosage of tobramycin used in commercial products such as TOBI is about 2.25 
µg/mL after nebulization. This value was used as the starting point and was varied +/- 10% to 
determine sensitivity and to ensure the minimum inhibitory concentration (MIC) is achieved in 
the biofilm without exceeding toxic limits. The inhalation time of commercial products, when 
using a nebulizer, is described to be around 15 minutes. Again, this was used as a starting point 
and was varied +/- 10% to determine sensitivity and for optimization. The effects of varying the 
number of doses are difficult to determine with this model. The only criteria available for killing 9 
 
the bacteria is a minimum inhibitory concentration (MIC), but no exposure time requirement. 
The model was run with enough dosages to reach effective steady state (consistent peak/trough 
concentrations for each dose). The half-life of tobramycin is provided in the literature as a range 
of values from 1.8 – 2.2 hours. The extremes and mean of this range were used for the sensitivity 
analysis (mean +/- 10%). The diffusivity of tobramycin through the biofilm and tissue is not well 
defined in the literature. One publication provides a single value of 3.84×10
-10 m
2/s for 
tobramycin diffusion in an ex vivo biofilm. This value was varied +/- 20% due to the potential for 
high variability between biofilms in different patients and biofilms at different stages of biofilm 
development. A value for tobramycin diffusivity through tissue was not found in the literature. 
Instead, flux data for amoxicillin through a monolayer of epithelial cells was used to calculate an 
approximate diffusivity value of 1.62×10
-12  m
2/s. This parameter likely has a higher potential for 
error and was varied +/- 20% as well.  
The biofilm diffusivity has very little effect on the average biofilm and blood 
concentrations at both time points (Figure 6 a,b). For a +/-20% change in diffusivity, the largest 
difference in concentration is 1.94% for the average biofilm and blood concentrations after the 8 
hour off-period. The tissue diffusivity has a slightly larger effect on the concentrations, but is 
still rather small. For a +/-20% change in tissue diffusivity, the largest difference is 2.96% for the 
average biofilm concentration immediately after the dosage. Since these diffusivities have an 
insignificant effect on the solution (<5%) with a change of 20%, there is no need to investigate 
the parameters further. Although these parameters were approximated based on data that does 
not directly relate to this drug in this model, the sensitivity to these parameters is low enough that 
error in these parameters should not significantly affect the model.  
The administered dose obviously has a significant effect on the concentrations. The dose 
was varied by +/-10% which resulted in changes of 8.9% - 11.7% in blood and average biofilm 
concentrations. The elimination constant has the largest effect on both the average biofilm 
concentration and the blood concentration after the 8 hr off-period. Differences of approximately 
15.8% were seen in these concentrations when the half-life was decreased by 10%. Unlike the 
dose concentration, the dosage administration time did not have a significant effect on the 
model.  From changing the data from a 15 minute administration to a 13.5 minute administration, 
we found that there is a <2% change in the biofilm and blood concentration after dosage and 
after 8 hours; similar results were seen with a 16.5 minute administration time (Table 1).  These 
low values show that our model is not sensitive to changes in the drug administration time and 
the initial specified time is sufficient for our purposes.   
The half-life of tobramycin was relatively well defined in the literature, so the mean 
value of 2 hrs was used in the model. The administration time had a surprisingly small effect on 
the average biofilm and blood concentrations. Since the biofilm is mostly water, it has a 
relatively large diffusion coefficient which allows the biofilm concentration to reach steady state 
quickly compared to administration time.  
It should be noted that all blood concentrations found in this analysis fell below toxic 
peak/trough concentrations stated in literature. Analysis of the aforementioned parameters 
indicates that optimization of treatment with tobramycin should focus mainly on changing the 
dosage concentration. 
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Figure 6. Sensitivity analysis of select parameters just after a 15 minute dosage of tobramycin (a) and 
after 8 hours following a dosage (b). The parameters were varied +/- 10% from the mean except for the 
diffusivity values (*) which were varied +/- 20% from the mean. 11 
 
Table 1. Difference in Solution, Compared with Mean Value, When Each Parameter is Varied  
 
Biofilm Diffusivity 
(3.84E-10 m^2/s) 
Tissue Diffusivity 
(1.62E-12 m^2/s) 
Dosage  
(2.25 μg/mL) 
Admin. Time 
(15 min) 
Half-life 
(2 hrs) 
  - 20%  + 20%  - 20%  + 20%  - 10%  + 10%  - 10%  + 10%  - 10%  + 10% 
Ave. Biofilm 
Concentration                               
after administration  0.02%  0.01%  2.96%  1.29%  10.00%  9.09%  0.01%  0.01%  0.00%  0.00% 
after off-period  0.11%  1.94%  2.61%  1.63%  11.68%  8.90%  1.27%  1.32%  15.74%  11.44% 
Blood 
Concentration                               
after administration  0.08%  0.15%  2.36%  1.07%  10.17%  8.98%  0.77%  1.27%  0.21%  0.17% 
after off-period  0.11%  1.94%  2.24%  1.04%  10.25%  8.90%  1.27%  1.32%  15.83%  11.52% 
 
Conclusion & Design Recommendations 
 
To optimize the dosage, we tested a variety of values to determine how much tobramycin 
was enough to not only kill the bacteria but sustain such a concentration in the biofilm over an 
extended time without reaching toxic levels in the body.  Since the MIC (4 μg/mL) was not met 
with the initial dosage of 2.25 µg/mL, a new dose concentration must be found that is high 
enough to inhibit the bacterial growth while maintaining safe limits (peak <12 µg/mL and trough 
<2 µg/mL). Consider the prescription information for these commercial antibiotics, which 
recommends dosing every 8 – 12 hours. If patients abide by this range, the trough concentration 
will be highest if they take antibiotics every 8 hours. To determine the appropriate dosage, the 
trough after 8 hours was compared with toxicity limits. Doing this showed that trough 
concentration increases linearly with the concentration administered (Table 2).  
Table 2. Trough blood concentration (µg/mL) after 2 doses 
Dose Concentration 
Trough Blood 
Concentration 
6  1.530 
6.5  1.657 
7  1.784 
7.5  1.912 
8  2.039 
If 7 µg/mL or higher was used as the dose concentration, the trough would be too close to 
or above the toxicity limit. These trough blood concentrations are given based on the average 
elimination constant for patients in the literature. A patient with less efficient kidneys may not 
have trough concentrations below the toxic limit. Our sensitivity analysis shows that changes in 
the elimination constant can result in significant changes in the solution (up to ~16% with 10% 
decrease in half-life). Therefore, we recommend that 6.5 µg/mL be the maximum dosage 
concentration. For this dose, the trough blood concentration is 17.2% below the toxic 
concentration. This will allow patients with less efficient kidneys to remain below toxic limits at 
a trough concentration of 1.90 µg/mL (Figure 7).  12 
 
 
Figure 7. Blood concentration of tobramycin over 2 dose cycles of 6.5 µg/mL. Removal of tobramycin 
from the blood is compared for average and less efficient kidneys 
 
  Inhibition of bacteria is simply defined by a MIC given in the literature. There is 
generally no exposure time specified for bacterial inhibition. For this model, the only design 
parameter that may be altered to increase exposure time is the dosage concentration. We will 
assume that maximizing exposure time for each dose is optimal. At the maximum allowable 
dosage concentration of 6.5 µg/mL, the bacteria in the biofilm are exposed to concentrations 
exceeding the MIC for approximately 3 hours per dose (Figure 8). Based on the findings with 
this model, the administration dosage should be 6.5 µg/mL to ensure bactericidal effects without 
poisoning the patients kidneys. 
 
 
Figure 8. Concentration of tobramycin in the center of the biofilm over 2 dose cycles at 6.5 µg/mL. 
Removal of tobramycin from the blood is compared for average and less efficient kidneys. 
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Realistic Constraints 
Because tobramycin inhalation solutions and nebulizers have successfully gained FDA 
approval and been marketed as TOBI and Tobamist, this implies that it has been approved as a 
safe treatment method, and no manufacturing or economic constraints are apparent. The most 
significant constraints on the results of this study are the physical assumptions within the model. 
For simplification, we assumed the air layer above the biofilm was stagnant in high generation 
alveoli, and thus there was no flux out during of the lungs between administrations. In lower 
generation alveoli, convection in addition to diffusion may be an important factor. Additionally, 
biofilm transport of antibiotics is still not well understood. Our model can only account for 
simple diffusion and is not able to consider binding effects, cellular uptake, or active transport by 
the cells. The concentration of aerosolized tobramycin may have been inaccurate as well – there 
was no data in the literature for the conversion of 60 mg/mL solution to a nebulized mist, so it is 
difficult to compare our dosage recommendation to the currently manufactured dosage (5).  
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Appendix A: Problem Formulation  
A1. Schematic: 
See the Problem Schematic section on page 4. 
A2. Governing Equations:  
The drug was modeled as two species: tobramycin in the bloodstream and tobramycin in 
the other three layers: air, biofilm, and alveolar wall. This is done to perform a mass balance 
between tobramycin entering the blood and tobramycin being removed by the kidney. The 
generation term for the concentration in the blood will be based on the flux of tobramycin out of 
the alveolar wall. This yields the following equations: 
(1) Diffusion of tobramycin through the air, biofilm and alveolar wall: 
 
where cA is the concentration of tobramycin in air, biofilm, and alveolar wall. DA is the 
diffusivity of the drug in the different layers. The diffusivity values are defined in the parameters 
section below.  
 
(2) Mass balance of tobramycin concentration in blood: 
 
where cB represents the concentration of tobramycin in blood and F is the flux of tobramycin 
entering the blood from the alveolar wall. A is the total alveolar surface area, and VB is the 
volume of blood in the body. k is the rate constant for the removal of tobramycin from the blood 
by the kidney, determined by a first order rate law using serum half-life from the literature. 
 
A3. Boundary & Initial Conditions:  
Boundary Conditions:  
  Top boundary condition varies with time. During the 15-minute nebulizer dosage, 
there is a constant concentration equal to the dosage concentration. For the 8 hours in 
between doses, there will be a zero flux boundary condition. We are assuming the air 
in this alveolus to be relatively stagnant, so once the drug is in the lower portion of 
the alveolar airspace, it will remain there until diffused into the biofilm.  
  The two side boundaries are considered insulated. 
  The bottom boundary is set at a constant concentration  equal to the blood 
concentration determined by the mass balance above. 
 
Initial Conditions:  
  Tobramycin concentration in all regions (air, biofilm, alveolar wall, blood) is zero at  
t = 0 (cT,0 = 0, cB,0 = 0).  
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A4. Parameters Used in Model:  
Parameter   Value   Source  
Dair, Diffusivity in air   4.98×10
-6 m
2/s   Calculated using Graham’s law 
compared with water vapor  
Dfilm, Diffusivity in biofilm   3.83×10
-10 – 5.56×10
-10 m
2/s  
References 13 and 14 (Note: 
measured diffusivity of 
tobramycin through pure water 
is 5.56×10
-10 m
2/s)  
Dalv, Diffusivity in alveolar wall   1.62×10
-12  m
2/s  
Based on Fick’s law calculation 
using flux and concentration 
data of amoxicillin diffusing 
through monolayer of epithelial 
cells (15) 
Dblood, Diffusivity in blood   5.56 ×10
-10 m
2/s   Assumed equal to water  
k, elimination constant   -9.627×10
-5 / s 
Based on a half life of 2 hrs and 
assuming a first order rate law 
(6) 
A, total alveolar surface area  58.9 m
2 
Based on alveolar radius, 
assuming spherical and 300 
million alveoli 
VB, total blood volume  5×10
-3 m
3   
 
Appendix B: Solution Strategy 
B1. Solver:  
The model was solved using the Direct (UMFPACK) finite element linear system solver 
in COMSOL.  
B2. Time Stepping:  
A time step of 30 seconds was used for the administration period, while a time step of 
300 seconds (5 minutes) was used for the off-period of 7 hours 45 minutes.  
B3. Solver Tolerance:  
Because this transient model is a relatively simple diffusion problem, we chose to use the 
default relative tolerance and absolute tolerance (0.01 and 0.001, respectively) to solve the 
model. 
B4. Mesh & Mesh Convergence:  
Because this model is essentially a 1-D problem, a structured mesh was chosen. Mesh 
convergence was performed using tobramycin concentration in blood (cB) as a point of reference 
after one 15-minute dosage. The blood concentration was used because it depends on the mesh of 
the entire model, an average value is not needed, and there is no potential interpolation error 
since it is a single calculated value. During mesh adjustment, the number of mesh elements in the 16 
 
y direction was adjusted using COMSOL’s presets; in the x direction, the number of elements 
was manually increased by 3 for each new mesh. CB stabilized at a final mesh size of 1010 
elements (“extremely fine”, 10 elements wide).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Final mesh: 1010 elements with 
constrained, 10 horizontal divisions 
and “extremely fine” vertical mesh 
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